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Abstract.
Background: Genetic factors that influence Alzheimer’s disease (AD) risk include mutations in TREM2 and allelic variants
of Apolipoprotein E, influencing AD pathology in the general population and in Down syndrome (DS). Evidence shows that
dysfunction of the choroid plexus may compromise the blood-cerebrospinal fluid (CSF) barrier, altering secretory, transport
and immune function that can affect AD pathology.
Objective: To investigate the genotype and phenotype of DS individuals in relation to choroid plexus damage and blood-CSF
barrier leakage to identify markers that could facilitate early diagnosis of AD in DS.
Methods: To assess allele frequency and haplotype associations ApoE, Tau, TREM2, and HLA-DR were analyzed by SNP
analysis in DS participants (n = 47) and controls (n = 50). The corresponding plasma protein levels were measured by ELISA.
Postmortem brains from DS, AD, and age-matched controls were analyzed by immunohistochemistry.
Results: Haplotype analysis showed that individuals with Tau H1/H1 and ApoE 4 genotypes were more prevalent among
DS participants with an earlier diagnosis of dementia (17%) compared to H1/H2 haplotypes (6%). Plasma TREM2 levels
decreased whereas phospho-tau levels increased with age in DS. In AD and DS brain, insoluble tau and ApoE were found to
accumulate in the choroid plexus.
Conclusion: Accumulation of tau and ApoE in the choroid plexus may increase the oligomerization rate of A42 and impair
tau trafficking, leading to AD pathology. We have identified a high-risk haplotype: ApoE 4, Tau/H1, and TREM2/T, that
manifests age-related changes potentially opening a window for treatment many years prior to the manifestation of the AD
dementia.
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INTRODUCTION
Down syndrome (DS) is the most common human
aneuploidy associated with intellectual disability and
early neurodegeneration. It is due to triplication of all
or part of chromosome 21, where genes, including the
amyloid precursor protein (APP) gene, that play key
roles in the pathogenesis of Alzheimer’s disease (AD)
are encoded. People with DS have an age-dependent
increased risk for developing dementia; effectively all
adults with DS over 40 years of age have excessive
numbers of senile plaques (SPs), consisting primarily
of amyloid- peptide (A) [1, 2]. The overexpression
of the APP gene may lead to excess A deposition,
occurring decades earlier in people with DS com-
pared to those in the typically developing population
with AD [3]. In addition to the appearance of SPs
and neurofibrillary tangles (NFTs) surrounded by A
plaques, aggregation of neuritic threads (NTs) and
neuropils (NPs) have also been found in DS brain [4,
5]. The microtubule associated protein tau (MAPT)
becomes hyperphosphorylated and aggregated, lead-
ing to the formation of NFT. Although dysfunction
of amyloid- protein precursor (APP) processing is
believed to be the key upstream factor in the patho-
genesis of AD [6], neuroinflammation and activation
of innate immunity are considered early events in the
genesis of AD and in DS dementia. In DS and in late-
onset AD, neuroinflammation has been linked to both
the exacerbation of SP and NFT pathology, as well as
the clearance of A from A plaques [7–9]. The main
cell types involved in neuroinflammatory responses
in the brain are microglia and to a lesser extent astro-
cytes [10, 11]. Microglia in the vicinity of the patho-
logical hallmarks of AD become activated and release
a variety of inflammatory cytokines and chemokines
[12]. Genome-wide association studies have shown
that a rare mutation of Triggering Receptor Expressed
on Myeloid cells (TREM2-R47H mutation) correlates
with a heightened risk of developing AD [13–16]. In
vitro studies indicate that TREM2 deficiency reduces
the efficacy of A clearance mechanisms and thus
can contribute to AD pathogenesis [17]. We have
recently provided evidence that in soluble TREM2
(sTREM2), the cleaved ectodomain of TREM2, pro-
tein levels decline with age and disease progression
in the brain and in the sera of people with DS [18].
Another key protein involved in AD and in the
risk of AD in DS is Apolipoprotein E (ApoE). This
gene is a major genetic risk factor for AD; 60–80%
affected individuals have at least one ApoE 4 allele
[19, 20]. ApoE 4 carriers develop A plaques earlier
than non-carriers. ApoE has been shown to impair the
metabolism of A and consequently decrease the rate
of A clearance from the brain [21–24]. Apolipopro-
teins, including ApoE and ApoJ, bind to TREM2 and
the uptake of A-lipoprotein complexes was reduced
in macrophages carrying the TREM2 /R47H muta-
tion [25]. However, the molecular mechanism and
cellular pathways by which TREM2, tau, and ApoE
influences A clearance and plaques deposition in
AD and in DS remain poorly understood.
We and others have previously provided evidence
that dysfunction of the choroid plexus (CP), which
results in altered secretory, transport, immune, and
barrier functions, contributes to normal aging and
the age-associated AD [26, 27]. The CP contains
fenestrated capillaries surrounded by tightly con-
nected choroid plexus epithelial (CPE) cells that form
the blood-cerebrospinal fluid barrier (BCSFB). The
major tasks of the CPE cells include cerebrospinal
fluid (CSF) production, removal of toxic waste prod-
ucts, and acting as gatekeepers of the brain by
ensuring the presence of resident inflammatory cells
[28]. The tight junctions located between the api-
cal parts of the CPE cells form part of the BCSFB,
which is crucial for the homeostatic regulation of the
brain microenvironment along with the blood-brain
barrier. Morphological changes, such as atrophy of
the epithelial cells and thickening of the basement
membrane, suggest altered CSF production occurs
with aging and in AD. Additionally, this structure
is important as an inflammatory sensor that detects
signals originating from both the peripheral and the
central nervous system [29, 30].
This is a longitudinal study; DS participants
(n = 47) were followed for six years by the Cam-
bridge Developmental Disabilities Research Group,
Cambridge, UK [31]. The aim of the study was to
evaluate both genotype and phenotype (plasma pro-
tein expression by ELISA), and to compare these
findings with positron emission tomography (PET)
imaging of DS participants as previously reported
[32]. Our second aim was to identify disease specific
haplotypes and finally to compare the AD pathology
involved in DS brain (in postmortem brain samples)
with age matched AD and control brain. All DS par-
ticipants had clinical evaluations and MRI and PET
scanning to the aid the diagnosis of dementia [31, 32].
Our new findings, supported by ongoing PET/MRI
neuroimaging data, could be developed into potential
biomarkers that could identify high-risk individuals
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suitable for pre-emptive therapy many years prior to
the manifestation of the dementia phenotype.
MATERIALS AND METHODS
Ethics and participants
Ethics and research and development (R&D)
approvals were granted by the National Research
Ethics Committee of the East of England – Nor-
folk and Cambridgeshire and Peterborough NHS
Foundation Trust, respectively, (Project ref no:
REC:15/WM/0379). Written consents were obtained
from controls (n = 50) and all adults with DS par-
ticipants (n = 47) with capacity to consent. Verbal
assent was obtained from participants with DS lack-
ing capacity to provide written assent, which was
provided instead by an appointed consultee, in accor-
dance with the Mental Capacity Act (2005) of the UK.
Assessment of dementia status
This was undertaken as described previously
using the CAMDEX-DS informant interview and the
CAMCOG-DS neuropsychological assessment [31].
Brain tissues
Human postmortem brain tissues from controls
(mean age 60 ± 15 years), DS (mean age 50 ± 15
years) and AD (mean age 82.0 ± 8.0 years) (N = 10 in
each group) were provided by the Cambridge Brain
Bank (Supplementary Table 1). Cambridge Health
Authorities Joint Ethics Committee granted ethical
approval for use of human brain tissue and serum
samples (Project ref no: REC:15/WM/0379).
Ethical approval for all procedures performed in
studies involving human participants were in accor-
dance with the ethical standards of the institutional
and/or national research committee and with the 1964
Helsinki declaration and its later amendments or
comparable ethical standards.
Blood and serum/plasma collection
Whole blood, serum, and plasma samples from
human controls (n = 50) and DS individuals (n = 47)
were collected for DNA and protein analysis at our
Research Centre during a six-year period from July
2012 to June 2018. Blood samples were collected into
EDTA tubes for DNA and plasma and serum blood
collection tubes. Serum and plasma were separated
immediately by centrifugation at 2465 g for 6 min at
4◦C, aliquoted, and stored at –80◦C until analysis.
Biochemical and hematological profiles were ana-
lyzed by pathology laboratories at Addenbrooke’s
Hospital, Cambridge University NHS Foundation
Trust, Cambridge.
Single nucleotide polymorphism analysis
and genotyping
Single nucleotide polymorphism (SNP) genotyp-
ing for TREM2 SNP (rs75932628, C-T encoding the
R47H variant), Tau (rs 9468, tagging MAPT, H1 ver-
sus H2 haplotypes) and HLA-DR (rs3129882 A/G
polymorphism) were performed using the TaqMan®
allelic discrimination assay on an HT7900 sequence
detection system (Applied Biosystems), according
to the manufacturer instructions. Genotyping suc-
cess rates were >96%. There were no inconsistencies
amongst 92 samples genotyped in duplicate. APOE
(2, 3, and 4) genotypes were analyzed by the
Genotype Facilities, East Anglia Medical Genetics
Service, Addenbrooke’s Hospital, Cambridge Uni-
versity Hospitals NHS Foundation Trust, Cambridge.
Antibodies
The following primary antibodies were used:
mouse monoclonal (mAb) anti-TREM2 (ab 201621,
MM0942-42E14) and rabbit mAb anti-TREM2
(ab209814) and other antibodies (Table S2) from
Abcam (Cambridge, UK). The mAb anti-A anti-
body (6E10) (Signet Laboratory) has been described
previously [18]. Other antibodies used in this study
including rabbit mAb anti-A antibodies (Abcam
ab201060) can be found in Supplementary Table 2.
The following secondary antibodies were used:
i.e., biotinylated goat anti-rabbit-Ig and biotinylated
horse anti-mouse (both from Vector Laboratories,
1:250 for IHC); Alexa Fluor 568-labelled don-
key anti-mouse-Ig, Alexa Fluor 488-labelled donkey
anti-rabbit-Ig; and Alexa Fluor 568-labelled don-
key anti-goat-Ig (all from Invitrogen, 1:1000 for
immunofluorescence).
Solid phase enzyme linked immunosorbent assay
(ELISA)
To quantify the concentrations of the soluble
extracellular domain of Triggering Receptor
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Expressed on Myeloid cells 2 (sTREM2) in human
EDTA-plasma samples, we adapted an anti-TREM2
ELISA system similar to that reported by Kleinberger
et al. [33]. For the detection of sTREM2, plates
were incubated overnight with mAb anti-TREM2
capture antibody (1g/ml) (Abcam, Cambridge).
The following day the plates were washed three
times with washing buffer (0.05% Tween 20 in 0.1 M
phosphate buffer saline (PBS) pH 7.4) and blocked
in blocking solution (1% BSA and 0.05% Tween 20
in 0.1M PBS) for 2 hours (2h) at room temperature
(RT). After blocking, the plates were washed three
times with washing buffer and loaded with 10l
plasma into 90l blocking solution and incubated
4 h at RT. A recombinant human TREM2 protein
(Life Technologies, Grand Isle, NY) was diluted in
assay buffer in a twofold serial dilution and used
for the standard curve with a concentration range
of 1000, 500, 250, 125, 62, 31, 15, and 0 pg/ml.
After 4 h of incubation, the samples were removed
and the plates were washed three times for 5 min
with washing buffer before incubation for 2 h at
room temperature for detection with a biotinylated
rabbit monoclonal anti-human TREM2 antibody
(1g/ml) diluted in blocking buffer. After three
further washing steps, the plates were incubated with
anti-rabbit HRP-conjugated secondary antibody
(1:4000) for 1 h followed by three washes. 100l of
1-Step ULTRA tetramethylbenzidine (TMB-ELISA,
ThermoScientific) was added for ∼30 minutes at
room temperature. Finally, 100l of 2 M H2SO4
was added to quench the reaction. The plates were
read with an Infinite m200 plate reader (Tecan)
at 450 nm.
Standard curve linearity and inter-plate and inter-
day variability for the sTREM2 ELISA were
determined using dedicated plasma sample anchors
for all plates. The specificity of the ELISA sys-
tem used was further validated by anti-TREM2
immunoblotting showing a high degree of correlation
between the ELISA readings and immunoreactiv-
ity on the immunoblot using these antibodies and
an independent anti-TREM2 antibody, mouse anti-
TREM2 2B5 (R&D Systems, Minneapolis, MN).
The plasma was stored at –70◦C until used for
further assays. Similar methods were followed for
amyloid-42 human ELISA kit (Catalog number:
KHB1 3544, Thermo Fisher scientific), A40 (Cat-
alog number: KHB1 3482, ThermoFisher scientific),
and ApoE (Abcam, Ab108813) with the ApoE kit
recognizing ApoE 2, ApoE 3, and ApoE 4
isoforms.
Measurement of total-tau and phospho-tau
by ultrasensitive immunoassay technique
Plasma total-Tau (t-Tau) was measured with the
Human Total Tau kit (Simoa™ Tau 2.0 Kit, Quan-
terix, Lexington, MA) in accordance with an updated
version of the previously described assay that uses a
monoclonal capture antibody that reacts with a linear
epitope in the mid region of all tau isoforms (phos-
phorylated and nonphosphorylated) and a detection
antibody that reacts with a linear epitope in the N-
terminus of t-Tau or phospho-tau (p-Tau). All samples
were analyzed in triplicate on one occasion. (Intra-
assay co-efficients of variance of the measurements
were less than 5%.) All cases and controls were
evenly distributed on the plate.
We measured levels of p-Tau in plasma by mod-
ifying an ultrasensitive immunoassay technique to
quantify plasma p-Tau phosphorylated at threonine
181 (p-tau181) instead of human total tau (Simoa™
Tau 2.0 Kit, Quanterix, Lexington, MA). We have
used a monoclonal capture antibody that reacts with
a linear epitope in the mid region of all tau iso-
forms and a detection antibody that reacts with an
epitope in the N-terminal region of t-Tau. Instead of
this detection antibody against t-Tau, we employed
anti-human PHF-tau monoclonal antibody AT270
(Thermo Fisher Scientific, Rockford, IL, USA) as
the detection antibody for p-Tau181 immunoassay.
This set of capture and detection antibodies specif-
ically reacts with p-Tau181 without reacting with
other phosphorylated tau variants. All plasma sam-
ples were diluted 4 times with the Tau 2.0 sample
diluent prior to the assays, to minimize matrix effects.
To eliminate inter-assay variability as a confound-
ing factor, all plasma samples belonging to the same
cohort were run in duplicate on the same day with the
same set of standards. The relative concentration esti-
mates of plasma p-Tau181 were calculated according
to a standard curve.
Immunofluorescence
Brain sections were blocked using blocking buffer
(0.1 M PBS, 0.3% Triton X100, 10% normal donkey
serum) for 1 h at room temperature, then incubated
overnight at 4◦C with primary antibody diluted in
blocking buffer. Alexa Fluor-conjugated secondary
antibodies were used for detection and samples
counterstained with 4′6-diamidino-2-phenylindole
(DAPI, Sigma). Sections were then mounted on
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glass slides with coverslips using Fluoro Save
(Calbiochem).
Microscopy
Bright field images were taken and quantified
using Lucia imaging software and a Leica FW 4000
upright microscope equipped with a SPOT digital
camera. Fluorescence images were obtained using a
Leica DM6000 wide field fluorescence microscope
equipped with a Leica FX350 camera with x20 and
x40 objectives. Images were taken through several
z-sections and de-convolved using Leica software. A
Leica TCS SP2 confocal laser-scanning microscope
was used with x40 and x63 objectives to acquire high-
resolution images.
Image and statistics analysis
All sections for IHC and plasma samples for
ELISA were performed in triplicate. Values in the
figures are expressed as mean ± SEM. A one–way
ANOVA was used for data comparison between con-
trol and DS. ANOVA was conducted with IBM-SPSS
statistic19 software. Differences were considered as
statistically significant at p < 0.01.
RESULTS
Genotype frequency and haplotype co-relation
between TREM2, ApoE, Tau, and HLA-DR
in DS participants
It was reported that the haplotypes of both ApoE
and Tau have been linked to AD and other neu-
rodegenerative diseases including in frontotemporal
dementia, Huntington’s disease, and Parkinson’s dis-
ease. We therefore examined alleles and genotype
frequencies for TREM2 (R47H) C/T mutation, ApoE
haplotypes (ApoE, 2, 3, and 4 alleles), Tau (rs
9468, tagging MAPT, H1 versus H2 haplotypes), and
HLA-DR (rs3129882 A/G polymorphism) by SNPs
analysis to determine allele prevalence in DS (n = 47,
Table 1). The frequency of the TREM2, R47H C-
allele was (0.95) and T allele (0.05) in our DS cohort.
Only two DS subjects out of 47 carried the C/T muta-
tion, a similar frequency to that previously reported in
the sporadic AD population. The frequency of ApoE
alleles in DS were as follows: 2/3 (0.2), 3/3
(0.52), and 3/4 (0.28, Table 1). The 4 frequency
was higher in DS compared to control and AD (con-
trol frequency: 2/3, 0.066; 3/3, 0.85, and 3/4,
0.08). Thirty-one percent of the DS participants car-
ried one ApoE 4 allele and none were homozygous;
one DS participant (D4, 39 years old, Table 2) with
TREM2 R47H (T allele) was heterozygous for ApoE
(3/4). Five years previously, at the first visit, D4
was cognitively normal, but slowly deteriorated and
then developed dementia. However, D7 (37 years old)
was homozygous for ApoE (3/3) and still has no
clinical symptoms of dementia yet (Table 2). The fre-
quency of 2 alleles in our DS cohort was higher than
average (0.11), and interestingly nearly all DS par-
ticipants above 50 years of age were either carrying
3/3 or 3/2 haplotypes and had been cognitively
normal at first visit (2012) only developing demen-
tia later. The only older DS participant in the cohort
(D18, 55 years old male) who carried the ApoE 3/4
haplotype had dementia from the time of diagnosis at
his first visit (Table 2).
The Tau genotypes, which are found in two forms
known as H1 and H2 haplotype, and H1 allele has
been reported to be associated with the early-onset
AD in the presence of an ApoE 4 allele [34]. In DS
participants, the frequency of haplotypes were as fol-
lows: H1/ H1 (0.59), H1/H2 (0.31), and H2/H2 (0.09)
in contrast to that in the control population (0.54,
0.33, and 0.13) (Table 1). Tau H2 homozygous fre-
quency was lower (0.09) in the DS group compared
to the control population. The haplotype frequency
of Tau and ApoE 4 together was different between
those who developed AD dementia before 45 years
and those that developed dementia after 45 years
of age (p≤ 0.01). Haplotype analysis indicated that
individuals with Tau H1/H1 and ApoE 4 genotype
were more prevalent among DS participants (21%)
who had an earlier diagnosis of dementia compared
toApoE 4-TauH1/H2 (6%) andApoE 4-TauH2/H2
(2%) haplotypes (Table 2).
Table 1
Allele frequency of ApoE, Tau, TREM2 and HLA-DR in DS and
control population
ApoE Allele Frequency 3/3 2/3 3/4 p
Controls (n = 50) 0.85 0.066 0.08 ≤0.001
DS (n = 47, m25, f22) 0.52 0.2 0.28
Tau SNPs (rs9468) H1/H1 H1/H2 H2/H2
Controls (n = 50) 0.54 0.33 0.13 ≤0.05
DS (n = 47) 0.59 0.31 0.09
TREM2 (R47H) C/C C/T T/T
Controls (n = 50) 1.0 0.0 0.0 ≤0.0001
DS (n = 47) 0.95 0.05 0.0
HLA-DR (rs3129882) A/A A/G G/G
Controls (n = 50) 0.49 0.41 0.1 NS
DS (n = 47) 0.43 0.43 0.14
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Table 2
Extended haplotype among DS participants
Number ID Sex Age Dementia ApoE Tau TREM2 HLA-DR
Young N= 19
1 D1 M 36 N E3E4 H1/H1 C/C A/A⊗
2 D2 F 36 N>I E3E4 H1/H1 C/C A/G
3 D3 F 45 N>I E3E4 H1/H1 C/C A/A
4 D4 F 39 D E3E4 H1/H2 C/T A/A
5 D5 F 47 N E3E4 H2H2 C/C A/A
6 D6 F 45 N E3E3 H1/H1 C/C G/G
7 D7 M 37 N E3E3 H2/H2 C/T A/G
8 D8 F 36 N E3E3 H1/H2 C/C A/A
9 D9 M 36 N E2E3 H1/H1 C/C A/G
10 D10 M 41 N E2E3 H1/H2 C/C A/G
Older N= 27
11 D11 F 48 N E2E3 H2/H2 C/C G/G*
12 D12 M 46 N E3E3 H2/H2 C/C A/G
13 D13 F 51 N E2E3 H1/H1 C/C G/G
15 D14 F 46 D E3E4 H1/H1 C/C A/A
16 D15 M 49 Died E3E4 H1/H1 C/C A/A
17 D16 F 54 D E3E4 H1/H1 C/C A/A
17 D17 M 56 P E2E3 H1/H1 C/C G/G
18 D18 M 55 D E3E4 H1/H1 C/C A/G
19 D19 M 56 D E3E3 H1/H1 C/C A/A
20 D20 F 65 D E2E3 H1/H2 C/C A/A
N, normal; I, intermediate or mild dementia; D, dementia; P, possibly demented; *green font,
protective haplotypes; ⊗red font, high risk haplotypes; blue and black font are common haplo-
types. There were 19 young and 27 older DS patients analyzed. Ten different haplotypes were
shown from each group.
The extended haplotype of DS participants who
carried the TREM2 R47H mutation was impressive:
D7 (male, 37 years old, ApoE 3/3, Tau H2/H2,
TREM2C/T, and HLA-DR A/G) was non-demented,
whereas D4 was (female, 39 years old, carrying
ApoE 3/4, TauH1/H2, TREM2-C/T, and HLA-DR
A/A) developed dementia. Wild-type TREM2 carri-
ers D11 (female, 48 years old was carrying ApoE
2/3, Tau H2/H2, TREM2C/C, and HLA-DR G/G)
and D12 (male, 46 years old was carrying ApoE 3/3
Tau H2/H2, TREM2C/C, and HLA-DRA/G) had not
developed dementia, indicating that H2 homozygos-
ity could be protective in DS subjects (Table 2).
The HLA-DR, G allele frequency was slightly
higher but non-significantly in DS (control frequency
0.49, and in DS 0.56, Table 1). We have identified two
extended haplotypes in DS cohorts which are the
TREM2-C, HLA-DR-G, Tau-H2, and ApoE-2 vari-
ants as being a protective haplotype (C-G-H2-2)
and a high-risk or disease haplotype, the TREM2-
T, HLA-DR-A, Tau-H1, and ApoE-4 (T-A-H1-4)
(Table 2). Unfortunately, the number of DS samples
available for this study was too small to infer any sta-
tistical significance (n = 47). This analysis would be
interesting to be repeated with a larger cohort.
ApoE protein level was haplotype dependent and
soluble TREM2 and Aβ42 protein levels were age
dependent and declined in DS with dementia
progression
After identifying informative allelic effects, we
investigated whether there was any correlation
between TREM2, Tau, and ApoE allele frequency
and plasma protein concentration? We measured the
plasma protein levels of TREM2, ApoE, tau, and
A42 and A40 in DS and age-matched controls using
ELISA. We have divided DS subjects into two age
groups: a younger DS group (n = 19, age between
30–44 years), referred as Y-DS, and an older DS group
referred as O-DS (n = 27, age between 45–70 years).
sTREM2 levels were found to be significantly
higher in controls compared to DS (Fig. 1a,
R2 = 0.78, p≤ 0.0001). Furthermore, sTREM2
levels were higher in Y-DS than O-DS (horizontal
bars indicate median sTREM2 concentration per
group, Fig. 1b). This data is in agreement with our
previous findings that TREM2 serum protein levels
are age dependent and decrease with age and disease
progression in DS [18].
ApoE plasma levels were then measured in the
same samples by ELISA. The levels of ApoE
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were widely distributed in DS (R2 = 0.44, p≤ 0.001,
Fig. 1c). ApoE plasma levels were higher in older
controls compared to age-matched older DS (Fig. 1d).
Although we have ApoE genotype information of
the DS participants, it was not available for the
control subjects. Surprisingly, Y-DS subjects carry-
ing an ApoE 2 genotype had the highest plasma
ApoE (range between 118.2–188.5 pg/ml) compared
to O-DS (range between 49.1–97.7 pg/ml, p≤ 0.001,
Fig. 1d). In contrast, among the ApoE 4 carriers, lev-
els were comparatively lower in O-DS (range from
20.4–25.7 pg/ml) than in Y-DS (range 22.7–44.5
pg/ml, Fig. 1e). These data indicate that ApoE plasma
protein level is haplotype dependent, where ApoE 2
heterozygous carriers have higher ApoE levels than
ApoE4 heterozygous carriers (R = 0.78, p≤ 0.0001,
Fig. 1e).
We then measured t-Tau and p-Tau levels in
plasma of Y-DS versus O-DS participants (Fig. 1f,
g). The t-Tau levels were not significantly different
between the Y-DS (range 210.6–720.4 pg/ml, Fig. 1f)
and O-DS (range 240.8–712.6 pg/ml, R2 = 0.38,
p≤ 0.01, Fig. 1f, h, and i), whereas p-Tau was signif-
icantly higher in O-DS participants (range 29.3–75.5
pg/ml) compared to Y-DS (range 29.8–56.7 pg/ml,
R2 = 0.45, p≤ 0.001, Fig. 1g, j). Plasma A40 lev-
els were found to increase with age, in Y-DS the
range was 113.0–131.2 pg/ml and in O-DS the
range was 120.5–164.3 pg/ml (R2 = 0.77, p≤ 0.0001,
Fig. 1k), whereas A42 was 15.5–23.1 pg/ml in Y-
DS and in O-DS it was, 10.7–22.1 pg/ml (R2 = 0.56,
p≤ 0.0001, Fig. 1l). Surprisingly, plasma A42 level
decreased with age in DS participants (Fig. 1k, l).
Additionally, the A42/A40 ratio decreased with
age and disease progression in DS (0.12–0.18 in
Y-DS compared to 0.07–0.20 in O-DS (R2 = 0.66,
p≤ 0.0001, Fig. 1m). Among the Y-DS participants
(aged between 30–44 years), 36% of subjects who
were dementia-free at time of diagnosis had devel-
oped dementia within five years. In the O-DS group
(aged between 45–70 years), 26% participants were
A-positive as measured with PET-PiB (PET-[11C]-
Pittsburgh Compound-B) and had early dementia.
After five years, 52% of these O-DS participants had
developed dementia.
TREM2 and tau proteins did not co-localize with
Aβ42 senile plaques
To investigate whether there is any influence of
plasma protein in the periphery on protein expres-
sion in the brain parenchyma, the cellular location
of TREM2, tau, ApoE, and A42 was examined by
immunofluorescence staining on postmortem brains
sections from the superior frontal cortex (SFC), hip-
pocampus (HP), and mid temporal cortex (MTC) of
AD, DS, and age-matched controls (n = 10 in each
group: aged between 46 to 76 years, Supplementary
Table 1). Confocal images of DS MTC brain sections
showed many mature SPs with well-defined struc-
tures of amyloid protein positive depositions (stained
with A42, antibody) but which did not co-localize
with p-Tau (stained with AT8, antibody Ser202/Thr
205 epitope; see Fig. 2a-e). In DS brains, A42
positive plaques appeared considerably more dense
compared to age-matched AD brains (Fig. 2a-f). In
AD brains, AT8 positive p-Tau was visible in the cen-
ter of plaques but it did not appear to co-localize with
A42 positive SP (Fig. 2d, e). Confocal images from
AD and DS brain showed that both TREM2 and p-
Tau were visible in NTs and in NPs (Fig. 2f, g, i,
and j). However, in AD brain sections, p-Tau positive
NFT were visible in the periphery of plaques or in the
core of SPs (Fig. 1k, l). We previously reported that
TREM2 protein was present in the surviving neurons
and here we show that it is present in the NTs and
the NPs but it was not found within NFTs in the DS
brains [18].
Increased insoluble tau in the hippocampus
and in entorhinal cortex of DS brain
We then further explored the association and
expression of TREM2 and tau in the DS brain with
particular focus in the HP and entorhinal cortex. Sec-
tions of control, DS, and AD brains (n = 10 from each
group) were stained with anti-t-Tau (t-Tau, HT7 anti-
body) for control brains and anti-p-Tau (AT8) for
AD and DS brains. In a young control brain (C1, 45
years old, Supplementary Table 1), t-Tau (t-Tau, rec-
ognized by antibody HT7) and TREM2 co-localized
in the pyramidal neurons of the HP, CA1, dentate
gyrus granule cells, subiculum, cortical, and sub-
cortical areas (Fig. 3a–c). In another control (C2,
45 years old), t-Tau was present in pyramidal neu-
rons of CA1, CA3, and in the neurofilaments of
subiculum (Fig. 3d). In a younger DS subject (DS3-
b, 46 years old, with Braak stage 2, the youngest
DS subject in this cohort), TREM2 staining was
visible in the dentate gyrus granule cells. Insolu-
ble p-Tau was seen in the axonal pyramidal neurons
with limited co-localization with TREM2 (Fig. 3e).
Compared to an AD case (AD7, 88 years old, Sup-
plementary Table 1), where most of the granule cells
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Fig. 1. Plasma ApoE, soluble TREM, and A42 protein levels were declined in DS with dementia progression. Plasma protein levels
of TREM2, ApoE, tau, A42, and A40 in DS and age-matched controls were determined by ELISA. Levels of sTREM2 were found to be
significantly higher in controls compared to DS; R2 = 0.78, p≤ 0.0001 (a). Soluble TREM2 level is age dependent, decreasing with age and
disease progression in DS. Horizontal scattered bars indicate median sTREM2 concentration per group (b). The levels of ApoE was widely
distributed in DS, R2 = 0.44, p≤ 0.001 (c). ApoE plasma levels were higher in older controls compared to age-matched older DS as shown
by scattered plot (d). ApoE 2 carriers have higher ApoE levels than ApoE 4 heterozygous subjects, R2 = 0.78, p≤ 0.0001 (e). The total
tau (t-Tau) level was not significantly different between Y-DS compared to O-DS, R2 = 0.38, p≤ 0.01 (f) and shown by scattered plot (h, i).
Whereas p-tau was significantly higher in O-DS subjects compared to Y-DS, R2 = 0.45, p≤ 0.001 (g), and as shown by scattered plot (j).
The plasma A40 level was found to be increased with age, R2 = 0.77, p≤ 0.0001 (k), and A42 level was decreased with age, R2 = 0.56,
p≤ 0.0001 (l). The A42/A40 ratio, R2 = 0.66, p≤ 0.0001, decreased with age and dementia progression in DS (m).
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Fig. 2. TREM2 and tau proteins did not co-localize with A42 senile plaques in mid temporal cortex. Double immunofluorescence
staining and confocal images were performed on the mid temporal cortex (MTC) of AD and DS brain sections using rabbit monoclonal
anti-A42 (rab-mAb A42, green) and mAb anti-phospho-tau (AT8, red) antibody, DAPI for nuclear staining (Blue). A42 immunoreactivity
was visible in the senile plaques (SPs) but did not co-localize with p-Tau (a–e). In DS brain (DS8), the layer III of MTC stained for anti-A42
(green) and showed many mature plaques (f and h). TREM2 was only present around the SPs and visible in the neuropil thread (f and g).
Further staining of different cases of AD (AD3 and AD5, Supplementary Table 1) and images was captured by confocal microscopy, showed
that mature A42 positive SPs did not co-localize with p-Tau positive neurofibrillary tangles. Scale bar in a–c = 50m, d-k = 25m, and
l = 10m.
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Fig. 3. Increased insoluble tau in the hippocampus and in entorhinal cortex of DS brains. Confocal microscopy analysis was performed
on controls, AD, and DS brain sections particularly in the hippocampus (HP) and entorhinal cortex. Total anti-Tau (HT7) for control brains
and anti-p-Tau (AT8) for AD and DS were used and DAPI for nuclear staining. In a young control brain (C1, Supplementary Table 1),
t-Tau (recognized by HT7, green) and TREM2 (red) co-localized in the pyramidal neurons of HP, in dentate gyrus granule cells, subiculum,
cortical, and subcortical areas (a–d). In a younger DS subject (DS3-b, Braak stage 2, Supplementary Table 1), TREM2 was visible in the
dentate gyrus granule cells and insoluble p-Tau in the pyramidal neurons (in the axons) with limited co-localization (e-g). In AD brains,
limited TREM2 expression was seen in the HP and did not co-localized with Iba1 positive activated microglia (f). Confocal images of a DS
brain (DS3), TREM2, and p-Tau co-localized in the axons (g-i), but TREM2 was not visible in neurofibrillary tangles (j). In an AD brain
section (AD2), TREM2 proteins were present in the cell body, whereas p-Tau was visible in the neuritic threads, neurofibrillary tangles, and
damaged axons (k). TREM2 levels were highest in controls and lowest in AD brains (l, p≤ 0.0001). Scale bar in a–f = 50m, g–k = 25m.
Image intensity measured by Image J. Error bars indicate SEM, ∗∗p < 0.001, ∗∗∗p < 0.0001.
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were damaged, Iba1 positive (microglial marker)
cells were present close to the damaged neurons but
minimal TREM2 expression was seen (Fig. 3f). Con-
focal analysis of the DS3-b brain showed very limited
TREM2 co-localization with p-Tau in NTs (Fig. 3g-
i). In an older DS brain from the MTC (DS1-b, 56
years of age, Braak stage 6), p-Tau positive mature
SPs and NFTs were observed but TREM2 was only
visible in partially damaged neurons in the surround-
ing area and did not co-localize with p-Tau positive
cells (Fig. 3j). In another AD (AD2, 88 years old)
brain section, both proteins were present in the cell
body whereas p-Tau was visible in the NT, NFT, and
damaged axons (Fig. 3k). Note that TREM2 levels
were highest in control and lowest in AD (Fig. 3l,
p≤ 0.001).
TREM2 expression was reduced in white matter
tracts in DS brain
Our PET image analysis data indicated that there
was narrowing of white matter tracts (WMT) and
enlargement of putamen volume in DS brain [31]. We
therefore analyzed WMT in SFC, striatum (STR) and
corpus callosum (CC) of control, AD, and DS brains
with anti-TREM2, and anti-t-Tau (HT7) or anti-p-Tau
(AT8). In control brains, in white matter (WM) and
SFC gray matter, TREM2 and t-Tau co-localized in
cortical neurons, particularly in the axons (Fig. 4a–c).
In DS brain sections, p-Tau and limited TREM2 were
present in the WM of cortex and in STR (Fig. 4e, h). p-
Tau expression was found to be higher in NTs than in
NFTs in DS brains and it had limited co-localization
with TREM2 (Fig. 4e). Similarly, in AD brain, partic-
ularly in WMT and in STR, large numbers of p-Tau
positive NTs and NFTs were visible (Fig. 4f & i). In
control brains, t-Tau protein was present in the WMT
of STR and in the CC, with strong co-localization
with TREM2 and t-Tau (Fig. 4g). Furthermore, in
the DS brain, WMT was damaged and there was
a high degree of infiltration with of Iba1 positive
microglia (Fig. 4h). Additionally, in the DS brain tis-
sue, WMTs of the CC were shrunken (atrophic), and
some MBP (mature oligodendrocyte marker) positive
oligodendrocytes present were positive for TREM2
(Fig. 4j–l). Notably, both proteins (TREM2 and tau)
were detected in WMT in controls and AD cases
but with a reduced expression in DS, indicating WM
damage in DS brain may involve atrophy (Fig. 4j–i,
m, and n). TREM2 levels were higher in WMT of
control and AD compared to DS brains (Fig. 4o,
p≤ 0.001).
p-Tau aggregates and ApoE were visible in the
fenestrated capillaries of choroid plexus and
sTREM2 in macrophages
As previously, we have found that the CP is dam-
aged in AD brain and in an AD mouse model and
as CP is a conduit between the peripheral circula-
tion and central nervous system via the CSF, we
extended our investigation to the CP in DS brain [26].
The CP is a complex structure, which hangs inside
the ventricles of the brain and consists mainly of
CPE cells surrounding fenestrated capillaries. CSF
is formed by the CPE and many soluble proteins
can enter the brain parenchyma via the CP [35].
Brain sections containing CP in lateral ventricles
and third ventricles from control, AD, and DS tis-
sues were stained with anti-TREM2 and anti-tau or
anti-TREM2 and anti-ApoE antibodies. In control
brains, both TREM2 and anti-t-Tau were present in
CP cuboidal epithelial cells surrounding a core of fen-
estrated capillaries and connective tissues (Fig. 5a).
Some soluble t-Tau protein was visible inside fenes-
trated capillaries and TREM2 was visible in stromal
capillary (vesicles) and in the stromal macrophages
(Fig. 5a, b). In DS and AD brain, dense fibrillary
p-Tau was present in “psammoma” bodies (calcified
intracellular inclusion structures), and in the stroma
and TREM2 co-localized in the vesicles and in stro-
mal macrophages (Fig. 5c, d). Similarly, in controls,
both the TREM2 and ApoE protein were visible in
CPE cells and in stromal macrophages that appeared
normal and healthy in structure (Fig. 5e), whereas
in DS brains, ApoE was visible in the “Amyloid
Biondi” bodies (complex filamentous ring-like struc-
tures associated with lipid droplets) and lipofuscin
(yellow or brown intracellular structures composed
of lipid molecules (Fig. 5f). In AD brains, epithelial
membranes of the CP were damaged and distorted,
and fibrillary p-Tau occupied fenestrated capillaries
that could potentially block the A clearance process
(Fig. 5d). These finding indicated that the CP-CSF
system exhibits morphological changes and a func-
tional decline with aging, in DS and in AD brain.
DISCUSSION
The most common form of DS is due to trisomy
21, and many neurobiological studies in older DS
participants have focused primarily on APP pro-
cessing and the temporal events that are thought to
lead to A pathogenesis [36, 37]. In addition to
A accumulation, middle-aged individuals with DS
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Fig. 4. TREM2 expression was reduced in white matter tracts in DS brains. White matter tracts (WMTs) are narrowed in DS brains as
shown by PET imaging data. Thus, WMTs and corpus callosum (CC) of control, AD, and DS brain sections were analyzed by immunoflu-
orescence using TREM2, t-Tau, or p-Tau antibodies. In control brains in the superior frontal cortex (grey matter), TREM2 (red) and t-Tau
(HT7, green) co-localized in cortical neurons (a–c), whereas in striatum (STR), WM-tract both proteins were present in oligodendrocytes
(d). In DS and AD brains, p-Tau (stained with AT8) were present in the in the neuropils and in neurofibrillary tangles and did not co-localize
with TREM2 (e and f). In control brains, t-Tau protein was present in the WMT of STR and in the CC (g). In DS brains in STR, WMT was
damaged and high infiltration of Iba1 positive microglial cells were visible (h). TREM2 did not co-localize with p-Tau positive SP in AD
brain sections (i). Confocal image of DS brain, WMTs of the CC were shrunken (atrophic), and some MBP positive oligodendrocytes were
co-localized with TREM2 (j-l). Both proteins (TREM2 and p-Tau) were detected in WMT in DS and AD cases but with reduced expression
in DS (m-n). TREM2 levels were higher in WMT of control and AD compared to DS (o, p≤ 0.001). Scale bar in a–c = 75m, d–i, m,
n = 25m, j–l = 20m. Image intensity measured by Image J. Error bars indicate SEM, ∗∗p < 0.001.
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Fig. 5. Phospho-tau aggregates and ApoE were visible in the fenestrated capillaries of choroid plexus and sTREM2 in the
macrophages. Brain sections containing choroid plexus (CP) in the lateral ventricles and third ventricles from control, AD, and DS
subjects were stained with anti-TREM2 and anti-Tau (t-Tau or p-Tau), or anti-TREM2 and anti-ApoE antibodies and analyzed by confocal
microscopy. DAPI was used for nuclear staining. In control brain, both TREM2 and anti-t-Tau were present in CP cuboidal epithelial cells
(CPE) surrounding a core of fenestrated capillaries and connective tissues (a). Some soluble t-Tau protein was visible inside fenestrated
capillaries and TREM2 was visible in stromal capillary (vesicles) and in the stromal macrophages (a and b). In DS and AD brain dense
fibrillary p-Tau present in psammoma bodies (calcified intracellular inclusion structures), was visible in the stroma and TREM2 co-localized
in the vesicles and in stromal macrophages (c and d). In control CP, both proteins TREM2 (red) and ApoE (green) were visible in CPE cells
and in stromal macrophages that appeared normal with healthy structure (e). In contrast, in DS brains ApoE was visible in the “amyloid
biondi” bodies (complex filamentous ring-like structures associated with lipid droplets, showing with an arrow) and lipofuscin (yellow or
brown intracellular structures composed of lipid molecules (f). Scale bar in a = 50m, b–f = 25m.
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develop NFTs, cerebrovascular pathology (cerebral
amyloid angiopathy), WM pathology, oxidative dam-
age, neuroinflammation, and neuronal loss [38]. A
accumulation is a very early event in the DS brain,
that includes formation of soluble A species with
different conformations of peptide such as oligomers,
protofibrils, and A-derived diffusible ligands, visi-
ble inside the cells, particularly in the neurons [39].
A40 and A42 have different properties for example:
A40 being more rapidly degraded within the lyso-
somes than the more toxic A42/43 species [40]. The
amount of A in the brain is also determined by its
clearance from the brain.
Apolipoprotein E (ApoE) is an important protein
that influences the clearance and metabolism of A
from brain parenchyma [41]. It has also been reported
that ApoE alleles modulate chronic inflammation
and some aspects of aging in brains and arteries
[42]. Blood ApoE mediates the clearance of triglyc-
eride and cholesterol-rich lipoprotein components,
and brain ApoE transports cholesterol to neurons
[43]. In general, the ApoE 4 allele shortens lifespan
by several years and accelerates degenerative changes
in arteries and brains [44]. The presence of an ApoE
4 allele doubles the cerebral amyloid plaque burden
and shortens lifespan in DS [45]. Furthermore, neu-
roinflammation, including the brain’s innate immune
response, is also recognized as a key component of
neurodegenerative disorders. In AD and DS, neuroin-
flammation has been linked to both the exacerbation
of amyloid plaques and NFTs in addition to increased
clearance of amyloid plaques. The discovery of the
R47H mutation in the TREM2 gene in AD and DS
established a closer link with immunity and neuroin-
flammation [18].
In this paper, we initially analyzed genotype and
haplotypic associations between all four genes (Tau,
TREM2, ApoE, and HLA-DR) and identified a “dis-
ease specific” and a “neuroprotective” haplotype. The
Tau gene located on human chromosome 17q21.31
and a 900 Kb inversion in Tau gene created H1
(the non-inverted sequence) and H2 (the inverted
sequence) haplotypes. The H1 haplotype is a risk
factor locus for progressive supranuclear palsy, cor-
ticobasal degeneration, Lewy body dementia, and
Parkinson’s disease [46]. In this paper in the DS
cohort, we have reported that individuals with a Tau
H1/H1 and ApoE 4 genotype were more prevalent
among DS participants (21%) who had an ear-
lier diagnosis of dementia compared to ApoE 4
and Tau H1/H2 haplotypes (6%). This data may
indicates that Tau H2 homozygosity could be pro-
tective in DS participants, as was previously reported
in AD [47].
As we reported, only two DS participants out of
47 who carried the TREM2-C/T mutation, and similar
frequency was previously reported in the AD popu-
lation [48]. One DS participant (D4, 39 years old)
with TREM2 R47H (T allele) who was heterozygous
for ApoE (3/4) slowly deteriorated and developed
dementia, whereas another DS participant (D7, 37
years old) who was homozygous for ApoE (3/3)
but had no clinical symptoms of dementia as yet. The
ApoE 2 allele has been associated with a decreased
risk of AD [49]. The frequency of 2 alleles in DS
was higher (20%), and interestingly nearly all DS
participants above 50 years of age who were either
carrying 3/3 or 3/2 haplotypes were cognitively
normal or developed dementia at a much later stage.
There was a correlation betweenTREM2-T,HLA-DR-
A, Tau-H1, and ApoE-4 (T-A-H1-4) and a high-risk
of dementia in contrast to TREM2-C, HLA-DR-G,
Tau-H2, and ApoE-2 haplotype, which was protec-
tive (C-G-H2-2).
To determine plasma protein level in DS, we
investigated TREM2, A42, A40, tau, and ApoE in
DS and age-matched controls using ELISA. Solu-
ble TREM2 protein levels declined and p-Tau level
increased in DS serum with age and dementia pro-
gression. We found that the effect of ApoE allele is
isoform specific in DS. The Y-DS participants carry-
ing ApoE 2 genotype had the highest plasma levels
compared to the O-DS participants. In contrast, those
with the ApoE 4 allele, the ApoE plasma levels
were comparatively lower in the O-DS than in the
Y-DS. These data indicated that ApoE protein levels
were haplotype dependent as were effects with age.
ApoE 2 heterozygous DS carriers have higher ApoE
serum protein levels than ApoE 4 heterozygous. The
majority (∼75%) of plasma ApoE is produced by
hepatocytes, creating a hepatic pool that is important
for lipid metabolism, while the second most com-
mon site of synthesis is the brain particularly in the
glial cells (astrocytes and microglia) [43]. The pro-
duction of different amounts of ApoE protein due to
different ApoE isoforms are likely to be due to their
amino-acid residue variation impacting the protein
structure. ApoE 2 carriers have two cysteines in 112
and 158 position, in ApoE 3 cysteine 158 is replaced
by an arginine whereas in ApoE 4 both cysteines
are replaced by arginines [43]. The changes of both
cysteines to arginines affects the helix structure and
binding capacity of many lipoproteins and choles-
terols due to Cys-Cys binding with many heme and
R. Raha-Chowdhury et al. / TREM2, Tau, and ApoE in Choroid Plexus in AD Pathology 105
iron proteins (Raha-Chowdhury, unpublished data).
In addition to the effects on fibrillogenesis, ApoE
is an A chaperone, promoting transport across the
blood-brain barrier, a process that is known to be
impaired in AD as a consequence of vascular damage
[50]. There are ApoE isoform-dependent differences
in the anti-inflammatory role in neurodegenerative
diseases and such differences might in part explain
the differential risk for AD caused by ApoE iso-
forms. In support of this hypothesis, several studies
demonstrated that exogenously applied ApoE 4 has
a more robust proinflammatory activity than ApoE
3 in astrocytes and microglial cells [51]. Besides
influencing brain aging, ApoE alleles also affect brain
development. Cortical neurons of young transgenic-
ApoE 4 overexpressing mice have less dendritic
complexity, which may be a factor in their impaired
spatial memory [52].
It is still debatable whether plasma or serum A
species can serve as reliable biomarkers for diagnosis
dementia or its prodromal stage in DS. According to
a large-scale meta-analysis in sporadic AD, plasma
t-Tau was the only blood biomarker with a suffi-
cient effect size [53]. To our knowledge, except for
one study, plasma p-Tau and t-Tau has been little
investigated in DS [54]. Plasma A species have
been expected to discriminate between demented
and non-demented individuals with DS and many
studies measuring plasma A species in DS agreed
that plasma levels of A species in DS were sig-
nificantly higher than those in normal individuals,
mainly because of overproduction of the APP [55].
Our aim in this study was to assess and compare
plasma levels of p-Tau and t-Tau with other blood
biomarkers including plasma A in adults with DS
and to compare with an age-matched control popu-
lation. We found that reproducible measurements of
plasma p-Tau were difficult to measure because of
its very low concentration in peripheral blood. We
found that the plasma A40 level was increased in
the O-DS group compared to the Y-DS and A42 lev-
els decreased with age in DS participants (R2 = 0.56,
p≤ 0.0001) as reported previously in AD in the typ-
ically developing population. Among Y-DS group
(aged between 30–44 years) there was a higher fre-
quency of ApoE 4 and 36% of participants who were
non-demented at baseline had developed dementia
within five years. In the O-DS subjects (aged between
45–70 years), 26% of participants who were PiB
positive and who had no dementia, but after five
years 52% of these O-DS participants had devel-
oped dementia. To our knowledge, this paper shows
for the first time a correlation between plasma pro-
teins and clinical phenotype changes in 47 adults DS
who underwent structural and amyloid PiB imaging
and in whom putative blood biomarkers identified a
high-risk group.
For cellular localization, we have examined post-
mortem DS, AD and control brain tissues (n = 10
in each group) by immunohistochemistry and ana-
lyzed by bright field or confocal microscopy,
using TREM2, tau (t-Tau and p-Tau), A40, A42,
and ApoE antibodies. Although many published
papers have reported TREM2 protein expression in
microglia [56, 57], we have shown for the first time
that TREM2 protein is expressed in human DS brains
particularly in the cortical and in HP neurons. Our
previous work showed that TREM2 mRNA was not
synthesized in the neurons, but it could be entering
the brain parenchyma and in the neuronal cells as
soluble TREM2 entirely from the periphery and that
it is involved in neuroplasticity [15]. In postmortem
brain sections of DS and AD, we showed that TREM2
and A42 were located in surviving neurons very
close to SPs in frontal and entorhinal cortices. We
have observed that, in young DS brains, A42 posi-
tive dense A accumulation (as cotton wool shaped)
were present and in some locations, particularly in
SFC and in MTC, and in older DS brain tissue these
plaques may progress in to fibrillary SPs. Tau protein
was visible in the periphery of dystrophic neurites
and of NFTs in AD brain. With disease progres-
sion, large swollen dystrophic neurites became NFT
and no TREM2 expression was seen to be associated
with A42 positive SPs or NFTs. Cotton wool shaped
plaques were present in DS brain in the absence of
NFTs, which may be due to the excess A accu-
mulation as a result of the gene triplication effect
of APP on Ch21. Although a large amount of A
(A40) exists in a soluble form, insoluble deposits
also begins to progressively form over time. In DS,
A accumulates in the neurons (intracellular), and
later as amyloid deposition. As deposition increases,
the A42/A40 ratio decreases leading to the forma-
tion of extracellular (A42) SPs. It is also apparent
that diffuse plaques precede neuritic plaques with age
in the cortex of DS subjects.
In the HP of normal brain, TREM2 and t-Tau
protein were visible in granule cells of the dentate
gyrus, supporting our recent publication regarding
TREM2’s involvement in neurogenesis [15]. Further-
more, the presence of TREM2 in axons and dendritic
processes of young DS brains and its co-localization
with p-Tau in NTs supports its role as a soluble trans-
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porter. In brain tissue obtained at postmortem from
younger people with DS, we observed AT8 positive
p-Tau in the molecular layer of HP, which was fol-
lowed later by NFT in the HP CA1 region and
subiculum, and neuronal loss in the entorhinal cor-
tex. In older DS brain tissue, p-Tau was visible in
the NFTs but without the expression of TREM2,
suggesting the presence of TREM2 protein only in
the unaffected neurons. In younger DS brain, a large
amount of t-Tau exists in a soluble form, and insol-
uble p-Tau begins to accumulate progressively over
time.
TREM2 expresses in oligodendrocytes in the
WMT, the olfactory bulb, CC, and STR bundles,
thus indicating that TREM2 protein may have a role
in myelination [15]. The loss of functional TREM2
could be a contributing mechanism in demyelination
deficits seen in DS and which would, in turn, increase
the susceptibility for neuronal loss [58]. Myelination
defects are one of the features of DS children that
may continue into adulthood with the potential to
accelerate neuronal loss and premature ageing. Brain
sections from DS, AD, and control cortex, the CC and
STR were stained with anti-TREM2 and anti-t-Tau
or anti-p-Tau (AT8). In control brains, t-Tau protein
was present in the WMT of STR and in the CC with
strong co-localization with TREM2. In contrast in
DS brains, STR was damaged and a high infiltration
of Iba1 positive microglia was visible, the WMTs
of the CC were shrunken (atrophic) and some MBP
positive oligodendrocytes (mature oligodendrocyte
marker) were positive for TREM2. Notably, both pro-
teins (TREM2 and tau) were detected in WMT in
controls and AD cases but with a reduced expression
in DS brain, indicating a role of TREM2 in axonal
transport with tau that could be impaired due to WM
defect in DS.
The CP plays a pivotal role in brain homeostasis.
Indeed, the structure, function and location of the
CP-CSF system has a significant influence on phys-
iological and pathological CNS functioning [59]. It
is the main source of CSF production and is respon-
sible for the removal of toxic waste products. The
CP may also be regarded as a “gatekeeper” of the
brain given the presence of resident inflammatory
cells [60]. In normal control brain, TREM2 protein
was highly expressed in the CP epithelial cells and
particularly in the stromal macrophages and close to
the ventricles and subarachnoid space. In DS and AD
brains dense fibrillary p-Tau present in “psammoma
bodies” (calcified intracellular inclusion structures),
was visible in the stroma, whereas in DS brains ApoE
was visible in the “amyloid biondi” bodies (complex
filamentous ring-like structures associated with lipid
droplets) and lipofuscin (yellow or brown intracellu-
lar structures composed of lipid molecules). Both in
AD and DS, CPE cell functionality is heavily affected
as is reflected by the loss of structural integrity and
changes in secretory activity. These might play a
central role in disease initiation or exacerbation or
maintenance of disease progression [61].
Many other immune molecules are located in the
extended HLA cluster (TREM2, TREMEL1, HLA-
DR, 1C7, and C1Q). These proteins could have
particular roles in different types of immune cells and
confer immunoprotective abilities [62]. The mecha-
nism by which an extra chromosome 21 produces
abnormalities in the immune system seen in ageing
in people with DS, including susceptibility to autoim-
mune diseases and recurrent infections, are still not
fully understood. The foundation for premature age-
ing in DS may be in part due to the triplication and
over expression of APP, which is encoded on chro-
mosome 21. Other genes may also play a role in
tau phosphorylation in DS brain as A42 upregulates
both DYRK1A [63] and RCAN1 [64], but this needs
further evaluation. Thus, overexpression of all three
genes in DS may co-operate to drive tau pathology
and neurodegeneration.
Conclusion
Although A overexpression in the brain is the key
gene defect in DS, three other genes, Tau, ApoE, and
TREM2, also could have a distinct role in A clear-
ance and neuroprotection. A vast amount of A enters
in the brain from periphery via blood and to be carried
by astrocytes and macrophages. In the initial stages
of the diseases processes, large numbers of activated
astrocytes and microglia were involved in the clear-
ance processes to prevent plaques formation, but with
the failure of that function A becomes trapped in
the SPs. Tau protein transport may be ApoE and
other lipoproteins dependent. We showed that ApoE
protein levels were haplotype dependent. The major
source of ApoE protein is synthesized in the liver
and carried via serum, entering the brain parenchyma
via CP epithelial cells and blood vessels, followed
by being taken up by astrocytes and other glia cells.
TREM2 protein enters via stromal macrophages of
CP and microglia as described above. All four pro-
teins orchestrated the task of protecting the brain
from neurodegeneration. Pharmacological targeting
of TREM2 to suppress the inflammatory response and
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modifying ApoE 4 isoform via CRISPA/cas9 may
provide a new approach for developing therapeutic
strategies in the treatment of neuroinflammation and
other neurodegenerative diseases.
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